Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ales) adjustment in respect of inventories acquired through the acquisition of Transkaryotic Therapies Inc. ("TKT"). Excluding the impact of this fair value adjustment, cost of sales as a percentage of product sales in 2006 was 13% in 2006. The increase in cost of sales as a percentage of product sales in 2007 over 2006 was primarily due to a shift in product mix resulting from increased sales of launched products, which had lower margins than existing products, and the write-off of inventory following the voluntary market withdrawal of a limited quantity of DAYTRANA patches.

For the year to December 31, 2007 cost of sales included a charge of US$5.3 million for share based compensation (2006: US$2.0 million) which included a US$2.1 million cumulative catch up charge (2006: US$nil) in respect of the 2005 option awards, for further information see SG&A below.

Research and development (R&D)

R&D expenditure increased to US$775.2 million for the year to December 31, 2007 (36% of product sales), up from US$295.8 million in the year to December 31, 2006 (19% of product sales).

The increase in R&D expenditure during the year to December 31, 2007 primarily relates to the following:

(i) a non-cash charge of US$100.0 million recognised on the effective settlement of Shire's pre-existing relationship with New River Pharmaceuticals Inc. ("New River"). This charge represents the write-off of capitalised up-front and milestone payments made by Shire prior to the acquisition of New River. This charge is presented within R&D as at the time of the New River acquisition VYVANSE, although approved by the FDA, had not yet received the final scheduling classification from the Drug Enforcement Agency ("DEA") and was therefore not available for commercial sale. Further details in respect of this charge are included in Note 3 of the Financial Statements; and

(ii) an intangible asset impairment charge for the year to December 31, 2007 of US$256.4 mi
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Xybion Medical ... its Research and Development facility in Fair Lawn, New Jersey. , ... Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion ... of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK ...
... , , , ... Inc. (Nasdaq: GHDX ) today reported financial results and business progress ... revenue increased to $36.6 million in the second quarter of 2009 compared with ... Onco type DX(R) breast cancer test was $35.2 million in the second ...
... 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,(ChemPartner) a wholly ... moved its drug discovery collaboration with ELARA,Pharmaceuticals to a ... the areas of DMPK, pharmacology and toxicology for ELARA,s ... from both sides will,work closely together to design and ...
Cached Biology Technology:SK Life Sciences has Licensed Pristima 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 9Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... LAFAYETTE, Ind. - Proper and timely burning of some Eastern ... a wide range of species, a Purdue University report shows. ... nutrient from deep in the soil and depositing it on ... an important source of nutrition for a variety of species ...
... been a hot savanna region for at least the past ... hominids evolved in this areasays a team of researchers led ... findings may shed light on the evolutionary pressures that led ... develop a more slender physique, and sweat more copiously than ...
... , New Rochelle, NY, June 8, 2010The growing use ... may help individuals with diabetes optimize blood glucose control ... with diabetes, as described in a Special Supplement to ... published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue ...
Cached Biology News:Fire may be key to reviving dogwood trees in Eastern forests 2East-African human ancestors lived in hot environments, says Caltech-led team 2East-African human ancestors lived in hot environments, says Caltech-led team 3Importance of insulin delivery devices for diabetes management 2